Michael Tian

Senior Analyst at Decision Resources Group covering the interventional #cardiology and interventional #oncology MedTech space. Providing updates at #TCT2018

[DRG - Medtech @DRGMedtech]

TALENT, DECISION, PRECISE and more - our vascular analysts look back and weigh in on #TCT2018's key clinical trials. @cuspcancerleo @MikeT_DRG @smessengerDRG #medtech #medicaldevices #Cardiology https://t.co/Z4zRVzlA8o

[Stéphane Rinfret, MD SM @RinfretStephane]

#TCT18 yesterday, in 45 min of air time on our #CHIP #CTO live case, we failed septal surfing, failed AWE, failed StingRay... but succesfully connected to the LAD through an epicardial cc. Completed case with X-CART and LM-LAD stenting. Strength of hybrid approach. Pre and post.

[JACC Journals @JACCJournals]

In light of ULTIMATE Trial at #TCT2018, which do you prefer: Angiography-guided or IVUS-guided PCI? (Read full #JACC study: https://t.co/b7vtnYnUle)

[Michael Tian @MikeT_DRG]

Not a comprehensive cohort of pts but FAST-FFR results presented at #TCT2018 by @wfearonmd shows FFRangio matches pressure-wire FFR in sensitivity, specificity, and accuracy. Another technology to add to the physiology toolkit. @DRGMedtech @cuspcancerleo

[Yael L. Maxwell @TCTMD_Yael]

Welcome to the future. ⁦@jerd10⁩ presenting on how computers are as good as operators in determining PCI appropriateness. Wold you rely on technologies to help make these decisions? #tct2018

[Michael Tian @MikeT_DRG]

This is even with a high rate of post-dil in the angio group! Side note: Dr. Takashi Akasaka: "In ILLUMIEN we demonstrated non-inferiority of OCT to IVUS, so I think OCT needs a trial like ULTIMATE as well." @AbbottCardio @DRGMedtech @cuspcancerleo #TCT2018

[William Suh, MD @willsuh76]

ULTIMATE trial #TCT2018 #LBCT
IVUS guided PCI associated with lower TVF compared to angio guided.
In the IVUS group, optimal PCI had best outcomes - TVF only 1.6%.
#ImageFirst

[C. Michael Gibson MD @CMichaelGibson]

Is infrared spectroscopy to identify vulnerable plaque ready for use in clinical practice? #TCT2018

[Michael Tian @MikeT_DRG]

#LRP results presented by @ron_waksman at #TCT2018 showing high association of higher maxLCBI4mm to NC-MACE. Does this have a place in standard treatment planning? Grounds for referral to a follow up phsysiology assessments? @infraredx @DRGMedtech @cuspcancerleo

[Michael Tian @MikeT_DRG]

Have my doubts on whether #AI alone will replace the expertise of human operators. On the other hand, humans using AI will replace those who don't. We're seeing the beginnings of this in imaging such as with @HeartFlow FFRct or @CorindusInc @DRGMedtech #TCT2018

[David L. Fischman @fischman_david]

Will Mathematical Algorithms and #AI Replace My Role As An Interventional Cardiologist? @TCTConference @crfheart @TCTMD @JDawnAbbott1 @jaygirimd #TCT2018 #CardioEd #jobsecurity

[Michael Tian @MikeT_DRG]

DECISION and PRECISE trials will provide a more comprehensive multi-center views on FFR-CT technology and its applications into the heart team decision making process. Can we reduce unnecessary cath lab visits and improve outcomes? @HeartFlow @DRGMedtech @cuspcancerleo #TCT2018

[William Suh, MD @willsuh76]

Safety and efficacy of IABP vs Impella in PCI by @d_sukul

Impella associated with higher bleeding and increased death compared to IABP

Need #RCT4Impella!

#OralAbstracts #TCT2018

[Michael Tian @MikeT_DRG]

Amazing breakfast session at #TCT2018 on robotic PCI. Comparable technical and procedural success even in complex lesions, short learning curve, and the sky's the limit. "The discussion should not be 'why' robotic PCI, but 'why not?'" @CorindusInc @DRGMedtech @benliDRG

[Michael Tian @MikeT_DRG]

Numerous trials with polymer-free stents here at #TCT2018 with ReCre8, LEADERS FREE II, and SORT OUT IX rounding out day 2 Late Breaking Trials. BioFreedom stent getting a lot of attention with solid data. @DRGMedtech @cuspcancerleo

[Michael Tian @MikeT_DRG]

We're seeing growing efforts by Chinese and Indian manufacturers to produce technology that can rival existing products in safety and efficacy. Now backed by clinical data such as the TALENT study at #TCT2018 @DRGMedtech @cuspcancerleo

[Michael Tian @MikeT_DRG]

IMPERIAL 1-year results at #TCT2018. Superior patency over 12 months for @bostonsci Eluvia DES over Zilver PTX. Half the rate of clinical TLR. Panel asks whether these positive signs will be maintained in long term results? @DRGMedtech @famadorDRG

[Michael Tian @MikeT_DRG]

BIONYX 1 year results at #TCT2018. Non-inferiority and "amazingly low" stent thrombosis rates for @Medtronic Resolute Onyx (0.1%) and @BIOTRONIK_US Orsiro (0.7%) even in high % of very complex patients. Panel was impressed to say the least. @DRGMedtech @cuspcancerleo

[Michael Tian @MikeT_DRG]

New kids on the block. Positive results for both Orsiro and EluNIR stents in their respective trials. More support for reducing the "metallic footprint" of stents @DRGMedtech @BIOTRONIK_US @Medinol_Stents @cuspcancerleo #TCT2018

[Michael Tian @MikeT_DRG]

Significantly increased procedural success rates for repeat CTO PCI with subintimal plaque modification. A way to make the best out of a tough situation @DRGMedtech #TCT2018

[Michael Tian @MikeT_DRG]

Higher than expected rotorblation %, and an interesting trend towards increased stent usage per procedure. @DRGMedtech #TCT2018 #medicaldevice #medtech

[Yael L. Maxwell @TCTMD_Yael]

We’re transitioning to a more complex mix of cases done radially, as these graphs from BCIS show, according to Tim Kinnaird #TCT2018

[Michael Tian @MikeT_DRG]

Transition to radial access has led to a reduction in overall patient complications in the UK, even within left main patients. @DRGMedtech #TCT2018 #Cardiovascular #CHIP